kikuchi jiro

FacultyDivisionofStemCellRegulation,CenterforMolecularMedicine
Job titleAssociate ProfessorWeb site

Profile

Research Areas

  • Clinical internal medicine / Hematology

Research Activities

Papers(paper)

  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J, Koyama D, Mukai HY, Furukawa Y
    International journal of hematology Apr. 2014
  • Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.
    Tago K, Funakoshi-Tago M, Itoh H, Furukawa Y, Kikuchi J, Kato T, Suzuki K, Yanagisawa K
    Oncogene Jan. 2014
  • Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y
    PloS one 9 e90675 2014
  • Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, Furukawa Y
    Leukemia Dec. 2013
  • Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma.
    Hiraoka N, Kikuchi J, Koyama D, Wada T, Mori S, Nakamura Y, Furukawa Y
    Blood cancer journal 3 e169 Dec. 2013
  • Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells.
    Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K
    Acta haematologica 132 1-4 Dec. 2013
  • HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.
    Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B
    Oncogene 32 5471-5480 Nov. 2013
  • The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y
    The Journal of biological chemistry 288 25593-25602 Aug. 2013
  • [How to overcome the cell adhesion-mediated drug resistance in multiple myeloma].
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 513-521 Jun. 2013
  • Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Sugiyama K, Ohki M, Park SY, Furukawa Y
    PloS one 8 e60649 2013
Display all
Papers(paper)close
  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J, Koyama D, Mukai HY, Furukawa Y
    International journal of hematology Apr. 2014
  • Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.
    Tago K, Funakoshi-Tago M, Itoh H, Furukawa Y, Kikuchi J, Kato T, Suzuki K, Yanagisawa K
    Oncogene Jan. 2014
  • Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y
    PloS one 9 e90675 2014
  • Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, Furukawa Y
    Leukemia Dec. 2013
  • Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma.
    Hiraoka N, Kikuchi J, Koyama D, Wada T, Mori S, Nakamura Y, Furukawa Y
    Blood cancer journal 3 e169 Dec. 2013
  • Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells.
    Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K
    Acta haematologica 132 1-4 Dec. 2013
  • HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.
    Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B
    Oncogene 32 5471-5480 Nov. 2013
  • The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y
    The Journal of biological chemistry 288 25593-25602 Aug. 2013
  • [How to overcome the cell adhesion-mediated drug resistance in multiple myeloma].
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 513-521 Jun. 2013
  • Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Sugiyama K, Ohki M, Park SY, Furukawa Y
    PloS one 8 e60649 2013
  • Promoter methylation confers kidney-specific expression of the Klotho gene.
    Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M, Furukawa Y, Kusano E
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 4264-4274 Oct. 2012
  • Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells.
    Mitsunaga K, Kikuchi J, Wada T, Furukawa Y
    Journal of cellular physiology 227 1138-1147 Mar. 2012
  • Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8.
    Wada T, Kikuchi J, Furukawa Y
    EMBO reports 13 142-149 Feb. 2012
  • [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y, Hiraoka N, Wada T, Kikuchi J, Kano Y
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 138 26-32 Jul. 2011
  • Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
    Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, Oram SH, Göttgens B, Kiyokawa N, Miyagawa Y, Okita H, Akahane K, Zhang X, Kuroda I, Honna H, Kagami K, Goi K, Kurosawa H, Look AT, Matsui H, Inaba T, Sugita K
    Blood 116 962-970 Aug. 2010
  • Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
    Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y
    Blood 116 406-417 Jul. 2010
  • MSK1 activation in acute myeloid leukemia cells with FLT3 mutations.
    Odgerel T, Kikuchi J, Wada T, Shimizu R, Kano Y, Furukawa Y
    Leukemia 24 1087-1090 May 2010
  • Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.
    Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, Matsunaga T, Inukai T, Goto H, Altura RA, Sugita K, Arisaka O, Look AT, Inaba T
    The Journal of biological chemistry 285 1850-1860 Jan. 2010
  • Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors.
    Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y
    The Journal of biological chemistry 284 30673-30683 Oct. 2009
  • A novel missense mutation of ABCA1 in transmembrane alpha-helix in a Japanese patient with Tangier disease.
    Maekawa M, Kikuchi J, Kotani K, Nagao K, Odgerel T, Ueda K, Kawano M, Furukawa Y, Sakurabayashi I
    Atherosclerosis 206 216-222 Sep. 2009
  • Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway.
    Oka S, Nagatsuka Y, Kikuchi J, Yokote T, Hirabayashi Y, Hanafusa T, Ozawa K, Muroi K
    Leukemia & lymphoma 50 1190-1197 Jul. 2009
  • Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells.
    Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E
    Kidney international 75 1173-1183 Jun. 2009
  • Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K
    Oncogene 28 231-242 Jan. 2009
  • The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
    Odgerel T, Kikuchi J, Wada T, Shimizu R, Futaki K, Kano Y, Furukawa Y
    Oncogene 27 3102-3110 May 2008
  • CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL-1.
    Nonomura C, Kikuchi J, Kiyokawa N, Ozaki H, Mitsunaga K, Ando H, Kanamori A, Kannagi R, Fujimoto J, Muroi K, Furukawa Y, Nakamura M
    Cancer research 68 790-799 Feb. 2008
  • E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.
    Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K, Furukawa Y
    Stem cells (Dayton, Ohio) 25 2439-2447 Oct. 2007
  • Transfection of antisense core 2 beta1,6-N-acetylglucosaminyltransferase-1 cDNA suppresses selectin ligand expression and tissue infiltration of B-cell precursor leukemia cells.
    Kikuchi J, Ozaki H, Nonomura C, Shinohara H, Iguchi S, Nojiri H, Hamada H, Kiuchi A, Nakamura M
    Leukemia 19 1934-1940 Nov. 2005
  • Not core 2 beta 1,6-N-acetylglucosaminyltransferase-2 or -3 but -1 regulates sialyl-Lewis x expression in human precursor B cells.
    Kikuchi J, Shinohara H, Nonomura C, Ando H, Takaku S, Nojiri H, Nakamura M
    Glycobiology 15 271-280 Mar. 2005
  • Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
    Kikuchi J, Mimuro J, Ogata K, Tabata T, Ueda Y, Ishiwata A, Kimura K, Takano K, Madoiwa S, Mizukami H, Hanazono Y, Kume A, Hasegawa M, Ozawa K, Sakata Y
    The journal of gene medicine 6 1049-1060 Oct. 2004
  • Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
    Ogata K, Mimuro J, Kikuchi J, Tabata T, Ueda Y, Naito M, Madoiwa S, Takano K, Hasegawa M, Ozawa K, Sakata Y
    Gene therapy 11 253-259 Feb. 2004
  • Defective sorting to secretory vesicles in trans-Golgi network is partly responsible for protein C deficiency: molecular mechanisms of impaired secretion of abnormal protein C R169W, R352W, and G376D.
    Naito M, Mimuro J, Endo H, Madoiwa S, Ogata K, Kikuchi J, Sugo T, Yasu T, Kariya Y, Hoshino Y, Sakata Y
    Circulation research 92 865-872 May 2003
  • Identification of novel p53-binding proteins by biomolecular interaction analysis combined with tandem mass spectrometry.
    Kikuchi J, Furukawa Y, Hayashi N
    Molecular biotechnology 23 203-212 Mar. 2003
  • Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter.
    Mimuro J, Muramatsu S, Hakamada Y, Mori K, Kikuchi J, Urabe M, Madoiwa S, Ozawa K, Sakata Y
    Gene therapy 8 1690-1697 Nov. 2001
  • Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation.
    Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M
    British journal of haematology 110 663-673 Sep. 2000
  • Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation.
    Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y, Matsuda M
    The Journal of biological chemistry 275 21661-21667 Jul. 2000
  • A simple semisolid subtraction method using carbodiimide-coated microplates.
    Kikuchi J, Furukawa Y, Suzuki O, Hayashi N, Nakamura M, Morita M, Matsuda M
    Molecular biotechnology 15 193-200 Jul. 2000
  • Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis.
    Kikuchi J, Furukawa Y, Kubo N, Tokura A, Hayashi N, Nakamura M, Matsuda M, Sakurabayashi I
    Arteriosclerosis, thrombosis, and vascular biology 20 128-134 Jan. 2000
  • An advantage for use of isotope labeling and NMR chemical shifts to analyze the structure of four homologous IgG-binding domains of staphylococcal protein A.
    Kikuchi J, Asakura T, Hasuda K, Ito T, Ohwaku K, Araki H, Williamson MP
    Journal of biochemical and biophysical methods 42 35-47 Jan. 2000
  • Regulation of macrophage-specific gene expression by degenerated lipoproteins.
    Furukawa Y, Kubo N, Kikuchi J, Tokura A, Fujita N, Sakurabayashi I
    Electrophoresis 21 338-346 Jan. 2000
  • Simultaneous core 2 beta1-->6N-acetylglucosaminyltransferase up-regulation and sialyl-Le(X) expression during activation of human tonsillar B lymphocytes.
    Nakamura M, Ishida T, Kikuchi J, Furukawa Y, Matsuda M
    FEBS letters 463 125-128 Dec. 1999
  • Beta(2)-microglobulin identified as an apoptosis-inducing factor and its characterization.
    Mori M, Terui Y, Ikeda M, Tomizuka H, Uwai M, Kasahara T, Kubota N, Itoh T, Mishima Y, Douzono-Tanaka M, Yamada M, Shimamura S, Kikuchi J, Furukawa Y, Ishizaka Y, Ikeda K, Mano H, Ozawa K, Hatake K
    Blood 94 2744-2753 Oct. 1999
  • Defective binding of IRFs to the initiator element of interleukin-1beta-converting enzyme (ICE) promoter in an interferon-resistant Daudi subline.
    Iwase S, Furukawa Y, Kikuchi J, Saito S, Nakamura M, Nakayama R, Horiguchi-Yamada J, Yamada H
    FEBS letters 450 263-267 May 1999
  • Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes.
    Furukawa Y, Iwase S, Kikuchi J, Nakamura M, Yamada H, Matsuda M
    Oncogene 18 2003-2014 Mar. 1999
  • UDP-GlcNAc:Galbeta1-->3GalNAc (GlcNAc to GalNAc) beta1-->6N-acetylglucosaminyltransferase holds a key role on the control of CD15s expression in human pre-B lymphoid cell lines.
    Nakamura M, Furukawa Y, Sasaki R, Masuyama J, Kikuchi J, Iwase S, Kudo T, Narimatsu H, Asakura S, Fujiwara S, Inokuchi J
    Glycobiology 9 1-12 Jan. 1999
  • Single glycosyltransferase, core 2 beta1-->6-N-acetylglucosaminyltransferase, regulates cell surface sialyl-Lex expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester.
    Nakamura M, Kudo T, Narimatsu H, Furukawa Y, Kikuchi J, Asakura S, Yang W, Iwase S, Hatake K, Miura Y
    The Journal of biological chemistry 273 26779-26789 Oct. 1998
  • A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome.
    Iwase S, Furukawa Y, Horiguchi-Yamada J, Nemoto T, Takahara S, Kawano T, Sekikawa T, Ito K, Yamazaki Y, Kikuchi J, Morishita K, Yamada H
    International journal of hematology 67 361-368 Jun. 1998
  • Bcl-x is a regulatory factor of apoptosis and differentiation in megakaryocytic lineage cells.
    Terui Y, Furukawa Y, Kikuchi J, Iwase S, Hatake K, Miura Y
    Experimental hematology 26 236-244 Mar. 1998
  • CMP-NeuAc:Gal beta 1-->4GlcNAc alpha 2-->6sialyltransferase catalyzes NeuAc transfer to glycolipids.
    Nakamura M, Tsunoda A, Yanagisawa K, Furukawa Y, Kikuchi J, Iwase S, Sakai T, Larson G, Saito M
    Journal of lipid research 38 1795-1806 Sep. 1997
  • Polyploidization and functional maturation are two distinct processes during megakaryocytic differentiation: involvement of cyclin-dependent kinase inhibitor p21 in polyploidization.
    Kikuchi J, Furukawa Y, Iwase S, Terui Y, Nakamura M, Kitagawa S, Kitagawa M, Komatsu N, Miura Y
    Blood 89 3980-3990 Jun. 1997
  • Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes.
    Kubo N, Kikuchi J, Furukawa Y, Sakai T, Ohta H, Iwase S, Yamada H, Sakurabayashi I
    FEBS letters 409 177-182 Jun. 1997
  • Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells.
    Iwase S, Furukawa Y, Kikuchi J, Nagai M, Terui Y, Nakamura M, Yamada H
    The Journal of biological chemistry 272 12406-12414 May 1997
  • Cell-cycle-dependent regulation of erythropoietin receptor gene.
    Komatsu N, Kirito K, Kashii Y, Furukawa Y, Kikuchi J, Suwabe N, Yamamoto M, Miura Y
    Blood 89 1182-1188 Feb. 1997
  • Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells.
    Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M, Kitagawa S, Kitagawa M
    The Journal of biological chemistry 271 28469-28477 Nov. 1996
  • Up-regulation of VLA-5 expression during monocytic differentiation and its role in negative control of the survival of peripheral blood monocytes.
    Terui Y, Furukawa Y, Sakai T, Kikuchi J, Sugahara H, Kanakura Y, Kitagawa S, Miura Y
    Journal of immunology (Baltimore, Md. : 1950) 156 1981-1988 Mar. 1996
  • Apoptosis during HL-60 cell differentiation is closely related to a G0/G1 cell cycle arrest.
    Terui Y, Furukawa Y, Kikuchi J, Saito M
    Journal of cellular physiology 164 74-84 Jul. 1995
  • Preferential production of interleukin-1 beta over interleukin-1 receptor antagonist contributes to proliferation and suppression of apoptosis in leukemic cells.
    Furukawa Y, Kikuchi J, Terui Y, Kitagawa S, Ohta M, Miura Y, Saito M
    Japanese journal of cancer research : Gann 86 208-216 Feb. 1995

Papers(other)

  • 多発性骨髄腫における薬剤耐性とその克服
    菊池次郎, 古川雄祐
    月刊血液内科 67(1) 112-122 Jul. 2013
  • 骨髄腫の診療の進歩 2 骨髄腫細胞と間質細胞の相互作用:薬剤耐性とその対策
    菊池次郎, 古川雄祐
    Bio Clin 27(13) 1212-1217 Dec. 2012
  • ヒストン脱アセチル化酵素阻害剤による多発性骨髄腫の治療
    菊池次郎, 古川雄祐
    医学のあゆみ 242(13) 1209-1214 Sep. 2012
  • 多発性骨髄腫研究の最近の進歩 ボルテゾミブの新たな作用機序と他剤との併用の理論的妥当性
    古川雄祐, 菊池次郎
    月刊血液内科 64(4) 424-431 Apr. 2012
  • 多発性骨髄腫に対する最新治療 2.多発性骨髄腫の薬剤耐性化とボルテゾミブの抗がん剤併用による抗腫瘍効果増強
    菊池次郎, 古川雄祐
    血液フロンティア 22(S-1) 625-633 Apr. 2012
  • Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine
    FURUKAWA Yusuke, HIRAOKA Nobuya, WADA Taeko, KIKUCHI Jiro, KANO Yasuhiko
    Folia Pharmacologica Japonica 138(1) 26-32 Jul. 2011
  • ヒストン脱アセチル化酵素阻害剤によるリツキシマブ耐性の克服
    古川雄祐, 清水瑠美, 和田妙子, 菊池次郎
    月刊血液内科 62(4) 499-506 Apr. 2011
  • Therapeutic Agents Targeting Myeloma Stem Cells
    66(3) 432-440 Mar. 2011
  • 細胞死と造血器腫瘍 多発性骨髄腫における細胞死の抑制
    古川雄祐, 菊池次郎
    月刊血液内科 62(2) 178-184 Feb. 2011
  • Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine
    FURUKAWA YUSUKE, HIRAOKA NOBUYA, WADA TAEKO, KIKUCHI JIRO, KANO YASUHIKO
    日本薬理学雑誌 138(1) 26-32 (J-STAGE) 2011
Display all
Papers(other)close
  • 多発性骨髄腫における薬剤耐性とその克服
    菊池次郎, 古川雄祐
    月刊血液内科 67(1) 112-122 Jul. 2013
  • 骨髄腫の診療の進歩 2 骨髄腫細胞と間質細胞の相互作用:薬剤耐性とその対策
    菊池次郎, 古川雄祐
    Bio Clin 27(13) 1212-1217 Dec. 2012
  • ヒストン脱アセチル化酵素阻害剤による多発性骨髄腫の治療
    菊池次郎, 古川雄祐
    医学のあゆみ 242(13) 1209-1214 Sep. 2012
  • 多発性骨髄腫研究の最近の進歩 ボルテゾミブの新たな作用機序と他剤との併用の理論的妥当性
    古川雄祐, 菊池次郎
    月刊血液内科 64(4) 424-431 Apr. 2012
  • 多発性骨髄腫に対する最新治療 2.多発性骨髄腫の薬剤耐性化とボルテゾミブの抗がん剤併用による抗腫瘍効果増強
    菊池次郎, 古川雄祐
    血液フロンティア 22(S-1) 625-633 Apr. 2012
  • Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine
    FURUKAWA Yusuke, HIRAOKA Nobuya, WADA Taeko, KIKUCHI Jiro, KANO Yasuhiko
    Folia Pharmacologica Japonica 138(1) 26-32 Jul. 2011
  • ヒストン脱アセチル化酵素阻害剤によるリツキシマブ耐性の克服
    古川雄祐, 清水瑠美, 和田妙子, 菊池次郎
    月刊血液内科 62(4) 499-506 Apr. 2011
  • Therapeutic Agents Targeting Myeloma Stem Cells
    66(3) 432-440 Mar. 2011
  • 細胞死と造血器腫瘍 多発性骨髄腫における細胞死の抑制
    古川雄祐, 菊池次郎
    月刊血液内科 62(2) 178-184 Feb. 2011
  • Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine
    FURUKAWA YUSUKE, HIRAOKA NOBUYA, WADA TAEKO, KIKUCHI JIRO, KANO YASUHIKO
    日本薬理学雑誌 138(1) 26-32 (J-STAGE) 2011
  • Recent advancement of myeloma stem cell research
    61(2) 206-211 Aug. 2010
  • リンパ球系 多発性骨髄腫における薬剤耐性機序
    古川雄祐, 菊池次郎
    Annual Review 血液 2010 139-145 Jan. 2010
  • 多発性骨髄腫―最近の進歩―骨髄腫細胞の薬剤耐性メカニズム
    古川雄祐, 菊池次郎
    最新医学 64(12) 2506-2511 Dec. 2009
  • Recent Advancement in Myeloma Stem Cell Research
    FURUKAWA YUSUKE, KIKUCHI JIRO
    Biotherapy (Tokyo) 23(5) 379-385 Sep. 2009
  • Down-regulation of VLA-4 expression by bortezomib in multiple myeloma cells
    59(3) 315-320 Sep. 2009
  • Role of E2F transcription factors in the development of hematologic malignancies
    58(2) 219-224 Feb. 2009
  • 幹細胞―基礎から臨床応用まで―がん幹細胞 骨髄腫幹細胞と微小環境
    古川雄祐, 菊池次郎
    最新医学 63(12) 2375-2380 Dec. 2008
  • 血液疾患と細胞周期~基礎から臨床まで~2.造血幹細胞の細胞周期特性
    菊池次郎
    血液フロンティア 17(11) 1647-1655 Oct. 2007
  • Study of Mechanical Evaluation of Protoplast Survivability
    KAWAMURA Yoshio, YOSHIBA Yosyu, TANAKA Shinji, SATO Kazuo, KIKUCHI Jirou, TAKAHASHI Kaoru
    Japanese journal of breeding 43(1) 91-99 Mar. 1993


Copyright c MEDIA FUSION Co.,Ltd. All rights reserved.